
    
      The purpose of the study is to determine the efficacy of 2 dose regimens of BC-3781 versus
      the licensed medicinal product vancomycin over 5 to 14 days. The population in this study
      will be patients with an acute bacterial skin and skin structure infection (ABSSSI) and they
      will receive treatment with one of two doses of BC-3781 or vancomycin, a standard treatment
      for this condition.
    
  